Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Aug 07, 2019 3:36pm

157 Views

Post# 30003587

RE:RE:Time for the "sarge"

Is Striking moose still around, would like to get his thoughts on activity in next 6 months.

qwerty22 wrote:

woundedknee wrote: Where is he anyway? Time for him to reappear and start posting that this will be 7 or 8 dollars. Don't get me wrong, I'm not being sarcastic, just wishing he was in the ballpark. If things are this good, with what Antibe has in their pipeline; i'm thinking maybe a buyout. jmo gl

Buyout : yes
Sarge : no